<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02427802</url>
  </required_header>
  <id_info>
    <org_study_id>INN-TOP-004</org_study_id>
    <nct_id>NCT02427802</nct_id>
  </id_info>
  <brief_title>Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers</brief_title>
  <acronym>COACT-1</acronym>
  <official_title>A Phase 3 Randomized, Placebo-Controlled, Blinded Study to Investigate the Safety and Efficacy of a Topical Gentamicin-Collagen Sponge in Combination With Systemic Antibiotic Therapy in Diabetic Patients With an Infected Foot Ulcer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innocoll</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innocoll</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3, randomized, controlled, blinded, multicenter study conducted in 3 parallel&#xD;
      cohorts of diabetic patients with at least 1 infected foot ulcer. Patients will be randomized&#xD;
      to receive 1 of 3 study treatments; systemic antibiotic therapy and standard ulcer care with&#xD;
      either (A) daily application of a gentamicin-sponge, (B) daily application of a&#xD;
      placebo-sponge or (C) no-sponge, in the ratio 2:1:1.&#xD;
&#xD;
      Patients will be treated for approximately 28 days and return to the clinic weekly for safety&#xD;
      and efficacy assessments. After completing treatment, patients will return to the clinic for&#xD;
      scheduled follow-up visits approximately 10, 30, 60 and 90 days after treatment is stopped.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 3, randomized, controlled, blinded, multicenter study conducted in 3 parallel&#xD;
      cohorts of diabetic patients with at least 1 infected foot ulcer. Patients will be randomized&#xD;
      using an electronic randomization system to receive 1 of 3 study treatments; systemic&#xD;
      antibiotic therapy and standard ulcer care with either (A) daily application of a&#xD;
      gentamicin-sponge, (B) daily application of a placebo-sponge or (C) no-sponge, in the ratio&#xD;
      2:1:1. The investigator will be blinded to the patient's treatment group assignment and&#xD;
      patients randomized to one of the 2 sponge groups will be blinded as to whether the sponge is&#xD;
      active or placebo.&#xD;
&#xD;
      If a patient has multiple infected ulcers, the assigned treatment will be administered to all&#xD;
      infected ulcers. The investigator will determine the highest severity ulcer to be used for&#xD;
      all efficacy evaluations and will also determine the size and number of sponges (up to 4)&#xD;
      that a patient will use in order to completely cover all infected ulcers. The investigator&#xD;
      will prescribe an empiric systemic antibiotic therapy based on protocol instructions.&#xD;
&#xD;
      Patients will be treated for approximately 28 days and return to the clinic weekly for safety&#xD;
      and efficacy assessments. The investigator will stop study treatment if a patient achieves&#xD;
      clinical cure by or after the 3rd treatment visit (approximately study day 15). After&#xD;
      completing treatment, patients will return to the clinic for scheduled follow-up visits or&#xD;
      until ulcer closure. The final efficacy assessments used in the primary efficacy analyses&#xD;
      will be obtained at the first follow-up visit approximately 10 days after treatment is&#xD;
      stopped. The remaining follow-up visits will occur at approximately 30, 60 and 90 days after&#xD;
      treatment is stopped when patients will be assessed for ulcer closure and any re-infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Cure (Resolution of All Clinical Signs and Symptoms of Infection)</measure>
    <time_frame>approximately 10 days after end of treatment</time_frame>
    <description>The primary efficacy variable is the percent of patients with a clinical outcome of clinical cure (Resolution of all clinical signs and symptoms of infection) at F/U visit 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Cure and Baseline Pathogen Eradication (Resolution of All Clinical Signs and Symptoms of Infection) and Baseline Pathogen Eradication)</measure>
    <time_frame>Approximately 10 days after end of treatment</time_frame>
    <description>Percent of patients with both a clinical outcome of clinical cure (Resolution of all clinical signs and symptoms of infection) and baseline pathogen eradication at F/U visit 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reinfection (Percent of Patients With Re-infection)</measure>
    <time_frame>Approximately 90 days after end of treatment</time_frame>
    <description>Percent of patients with re-infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Clinical Cure</measure>
    <time_frame>Approximately 10 days after end of treatment</time_frame>
    <description>Actual time to clinical cure (Resolution of all clinical signs and symptoms of infection)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amputation (Percent of Patients That Have an Amputation Associated With the Target Ulcer)</measure>
    <time_frame>Within approximately 90 days of end of treatment</time_frame>
    <description>Percent of patients that have an amputation associated with the target ulcer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ulcer Closure (Percent of Patients With Target Ulcer Closure)</measure>
    <time_frame>within approximately 30 days of end of treatment</time_frame>
    <description>Percent of patients with ulcer closure within approximately 30 days of end of treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">612</enrollment>
  <condition>Foot Ulcer, Diabetic</condition>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>Gentamicin sponge group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo sponge group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No sponge group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gentamicin collagen sponge</intervention_name>
    <description>Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)</description>
    <arm_group_label>Gentamicin sponge group</arm_group_label>
    <other_name>Cogenzia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching collagen sponge</description>
    <arm_group_label>Placebo sponge group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has diabetes mellitus, according to the American Diabetes Association (ADA) criteria.&#xD;
&#xD;
          -  Has at least 1 skin ulcer located on or below the malleolus that presents with the&#xD;
             following clinical manifestations of a moderate or severe infection based on the&#xD;
             Infectious Disease Society of America guidelines for the &quot;Diagnosis and Treatment of&#xD;
             Diabetic Foot Infections&quot; (CID 2012; 54:132-173) (IDSA guidelines):&#xD;
&#xD;
               -  has ≥ 2 manifestations of inflammation (local swelling or induration, erythema,&#xD;
                  local tenderness or pain, local warmth, purulent discharge (thick, opaque to&#xD;
                  white or sanguineous secretion)&#xD;
&#xD;
               -  has ≥ 1 of the following characteristics: erythema &gt; 2cm, or involving structures&#xD;
                  deeper than skin and subcutaneous tissues (e.g. abscess, osteomyelitis, septic&#xD;
                  arthritis, fasciitis) For patients with multiple infected ulcers, the ulcer with&#xD;
                  the highest Diabetic Foot Infection Wound score (DFI score) must be on or below&#xD;
                  the malleolus and all infected ulcers must be completely coverable using no more&#xD;
                  than 4 sponges (sponges cannot be cut).&#xD;
&#xD;
          -  Has documented adequate arterial perfusion in the affected limb(s) (either palpable&#xD;
             dorsalis pedis and posterior tibial pulses, or normal Doppler wave forms, a toe blood&#xD;
             pressure ≥ 45 mm Hg or participation is approved by a vascular surgeon)&#xD;
&#xD;
          -  Has received appropriate surgical intervention to remove all necrotic and infected&#xD;
             bone if diagnosed with osteomyelitis.&#xD;
&#xD;
          -  Has received appropriate surgical debridement to remove all gangrenous tissue.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a known history of hypersensitivity to gentamicin (or other aminoglycosides).&#xD;
&#xD;
          -  Has a known or suspected hypersensitivity to bovine collagen.&#xD;
&#xD;
          -  Has an ulcer infection which, based upon the patient's known history of&#xD;
             hypersensitivity and/or as otherwise in the opinion of the investigator, cannot be&#xD;
             adequately treated with at least one of the empiric systemic antibiotic regimens&#xD;
             allowed by this protocol.&#xD;
&#xD;
          -  Has an ulcer associated with prosthetic material or an implanted device.&#xD;
&#xD;
          -  Has received any systemic or topical antibiotic therapy for any reason within 7 days&#xD;
             of randomization unless it was administered to specifically treat the infected&#xD;
             ulcer(s) and only within 36 hours of randomization.&#xD;
&#xD;
          -  Requires or is likely to require treatment with any concomitant topical product or&#xD;
             wound therapy before the first follow-up study visit.&#xD;
&#xD;
          -  Is severely immunocompromised, or likely to become severely immunocompromised during&#xD;
             the study, in the opinion of the investigator.&#xD;
&#xD;
          -  Has a history of myasthenia gravis or other neurological condition where gentamicin&#xD;
             use is contraindicated as determined by the investigator.&#xD;
&#xD;
          -  Has a history of epilepsy.&#xD;
&#xD;
          -  Has a history of alcohol or substance abuse in the past 12 months.&#xD;
&#xD;
          -  Has an uncontrolled illness that, in the opinion of the investigator, is likely to&#xD;
             cause the patient to be withdrawn from the trial or would otherwise interfere with&#xD;
             interpreting the results of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nigel Jones</last_name>
    <role>Study Director</role>
    <affiliation>Vice President, Global Clinical Operations, Innocoll Pharmaceutical</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chino</city>
        <state>California</state>
        <zip>91710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corona</city>
        <state>California</state>
        <zip>92882</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93722</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sylmar</city>
        <state>California</state>
        <zip>91342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06851</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clermont</city>
        <state>Florida</state>
        <zip>34711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cooper City</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fleming Island</city>
        <state>Florida</state>
        <zip>32003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami Springs</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33185</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33326</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Avon</city>
        <state>Indiana</state>
        <zip>46123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mooresville</city>
        <state>Indiana</state>
        <zip>46158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Muncie</city>
        <state>Indiana</state>
        <zip>47304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Maryland</state>
        <zip>21131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Brunswick</city>
        <state>New Jersey</state>
        <zip>08902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Somerset</city>
        <state>New Jersey</state>
        <zip>08873</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hopewell Junction</city>
        <state>New York</state>
        <zip>12533</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Windsor</city>
        <state>New York</state>
        <zip>12553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lima</city>
        <state>Ohio</state>
        <zip>45801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lampasas</city>
        <state>Texas</state>
        <zip>76550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Richland Hills</city>
        <state>Texas</state>
        <zip>76180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 17, 2015</study_first_submitted>
  <study_first_submitted_qc>April 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2015</study_first_posted>
  <results_first_submitted>May 28, 2021</results_first_submitted>
  <results_first_submitted_qc>August 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 25, 2021</results_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gentamicins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gentamicin Sponge Group</title>
          <description>Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.&#xD;
Gentamicin collagen sponge: Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)</description>
        </group>
        <group group_id="P2">
          <title>Placebo Sponge Group</title>
          <description>Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.&#xD;
Placebo: Matching collagen sponge</description>
        </group>
        <group group_id="P3">
          <title>No Sponge Group</title>
          <description>Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="305"/>
                <participants group_id="P2" count="154"/>
                <participants group_id="P3" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="246"/>
                <participants group_id="P2" count="120"/>
                <participants group_id="P3" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="43"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>protocol specific treatment unrelated</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gentamicin Sponge Group</title>
          <description>Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.&#xD;
Gentamicin collagen sponge: Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)</description>
        </group>
        <group group_id="B2">
          <title>Placebo Sponge Group</title>
          <description>Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.&#xD;
Placebo: Matching collagen sponge</description>
        </group>
        <group group_id="B3">
          <title>No Sponge Group</title>
          <description>Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="305"/>
            <count group_id="B2" value="154"/>
            <count group_id="B3" value="153"/>
            <count group_id="B4" value="612"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.6" spread="10.84"/>
                    <measurement group_id="B2" value="57.1" spread="11.12"/>
                    <measurement group_id="B3" value="56.7" spread="11.16"/>
                    <measurement group_id="B4" value="57.3" spread="10.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="146"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="240"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="119"/>
                    <measurement group_id="B4" value="466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="305"/>
                    <measurement group_id="B2" value="154"/>
                    <measurement group_id="B3" value="153"/>
                    <measurement group_id="B4" value="612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Cure (Resolution of All Clinical Signs and Symptoms of Infection)</title>
        <description>The primary efficacy variable is the percent of patients with a clinical outcome of clinical cure (Resolution of all clinical signs and symptoms of infection) at F/U visit 1</description>
        <time_frame>approximately 10 days after end of treatment</time_frame>
        <population>modified intent to treat population consisted of randomized patients who received any dose of gentamicin-sponge or placebo-sponge or who were randomized to the no sponge arm, and who were not early-terminated for any of the treatment-unrelated reasons before F/U visit 1,</population>
        <group_list>
          <group group_id="O1">
            <title>Gentamicin Sponge Group</title>
            <description>Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.&#xD;
Gentamicin collagen sponge: Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Sponge Group</title>
            <description>Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.&#xD;
Placebo: Matching collagen sponge</description>
          </group>
          <group group_id="O3">
            <title>No Sponge Group</title>
            <description>Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cure (Resolution of All Clinical Signs and Symptoms of Infection)</title>
          <description>The primary efficacy variable is the percent of patients with a clinical outcome of clinical cure (Resolution of all clinical signs and symptoms of infection) at F/U visit 1</description>
          <population>modified intent to treat population consisted of randomized patients who received any dose of gentamicin-sponge or placebo-sponge or who were randomized to the no sponge arm, and who were not early-terminated for any of the treatment-unrelated reasons before F/U visit 1,</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cure and Baseline Pathogen Eradication (Resolution of All Clinical Signs and Symptoms of Infection) and Baseline Pathogen Eradication)</title>
        <description>Percent of patients with both a clinical outcome of clinical cure (Resolution of all clinical signs and symptoms of infection) and baseline pathogen eradication at F/U visit 1</description>
        <time_frame>Approximately 10 days after end of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gentamicin Sponge Group</title>
            <description>Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.&#xD;
Gentamicin collagen sponge: Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Sponge Group</title>
            <description>Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.&#xD;
Placebo: Matching collagen sponge</description>
          </group>
          <group group_id="O3">
            <title>No Sponge Group</title>
            <description>Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cure and Baseline Pathogen Eradication (Resolution of All Clinical Signs and Symptoms of Infection) and Baseline Pathogen Eradication)</title>
          <description>Percent of patients with both a clinical outcome of clinical cure (Resolution of all clinical signs and symptoms of infection) and baseline pathogen eradication at F/U visit 1</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reinfection (Percent of Patients With Re-infection)</title>
        <description>Percent of patients with re-infection</description>
        <time_frame>Approximately 90 days after end of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gentamicin Sponge Group</title>
            <description>Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.&#xD;
Gentamicin collagen sponge: Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Sponge Group</title>
            <description>Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.&#xD;
Placebo: Matching collagen sponge</description>
          </group>
          <group group_id="O3">
            <title>No Sponge Group</title>
            <description>Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Reinfection (Percent of Patients With Re-infection)</title>
          <description>Percent of patients with re-infection</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Clinical Cure</title>
        <description>Actual time to clinical cure (Resolution of all clinical signs and symptoms of infection)</description>
        <time_frame>Approximately 10 days after end of treatment</time_frame>
        <population>Modified Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Gentamicin Sponge Group</title>
            <description>Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.&#xD;
Gentamicin collagen sponge: Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Sponge Group</title>
            <description>Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.&#xD;
Placebo: Matching collagen sponge</description>
          </group>
          <group group_id="O3">
            <title>No Sponge Group</title>
            <description>Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Clinical Cure</title>
          <description>Actual time to clinical cure (Resolution of all clinical signs and symptoms of infection)</description>
          <population>Modified Intent-to-Treat Population</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="30.0" upper_limit="NA">Upper boundary not reached</measurement>
                    <measurement group_id="O2" value="33" lower_limit="29.0" upper_limit="NA">Upper boundary not reached</measurement>
                    <measurement group_id="O3" value="46" lower_limit="30.0" upper_limit="NA">Upper boundary not reached</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amputation (Percent of Patients That Have an Amputation Associated With the Target Ulcer)</title>
        <description>Percent of patients that have an amputation associated with the target ulcer</description>
        <time_frame>Within approximately 90 days of end of treatment</time_frame>
        <population>Modified Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Gentamicin Sponge Group</title>
            <description>Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.&#xD;
Gentamicin collagen sponge: Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Sponge Group</title>
            <description>Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.&#xD;
Placebo: Matching collagen sponge</description>
          </group>
          <group group_id="O3">
            <title>No Sponge Group</title>
            <description>Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Amputation (Percent of Patients That Have an Amputation Associated With the Target Ulcer)</title>
          <description>Percent of patients that have an amputation associated with the target ulcer</description>
          <population>Modified Intent-to-Treat Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ulcer Closure (Percent of Patients With Target Ulcer Closure)</title>
        <description>Percent of patients with ulcer closure within approximately 30 days of end of treatment</description>
        <time_frame>within approximately 30 days of end of treatment</time_frame>
        <population>Modified Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Gentamicin Sponge Group</title>
            <description>Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.&#xD;
Gentamicin collagen sponge: Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Sponge Group</title>
            <description>Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.&#xD;
Placebo: Matching collagen sponge</description>
          </group>
          <group group_id="O3">
            <title>No Sponge Group</title>
            <description>Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Ulcer Closure (Percent of Patients With Target Ulcer Closure)</title>
          <description>Percent of patients with ulcer closure within approximately 30 days of end of treatment</description>
          <population>Modified Intent-to-Treat Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>approximately 28 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Gentamicin Sponge Group</title>
          <description>Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.&#xD;
Gentamicin collagen sponge: Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)</description>
        </group>
        <group group_id="E2">
          <title>Placebo Sponge Group</title>
          <description>Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.&#xD;
Placebo: Matching collagen sponge</description>
        </group>
        <group group_id="E3">
          <title>No Sponge Group</title>
          <description>Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>cardiac failure congestive</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>cardiac failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>mitral valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diabetic gastroparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>impaired gastric emptying</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>device extrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>osteomyelitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="305"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>infected skin ulcer</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>cellulitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>osteomyelitis acute</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>sepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>abscess limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>gangrene</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>localised infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>osteomyelitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>post procedural infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>streptococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>stab wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>diabetes mellitus inadequate cotnrol</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>metabolic acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Mueller's mixed tumour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>diabetic hyperosmolar coma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>acute kidney injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>chronic kidney disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>penile necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>pulmonay embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>pulmonary mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin ulcer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>decubitus ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>peripheral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="305"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="305"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="154"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="305"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="305"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="154"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infected skin ulcer</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="305"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="154"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="305"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="154"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="305"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="305"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="305"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Upper Respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="305"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="154"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Type 2 diabetes Mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="305"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="305"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin ulcer</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="305"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="154"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="305"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Results of the multicenter study had to be published prior to the publication of any site specific data.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lesley Russell, MBChB, MRCP, Chief Medical Officer</name_or_title>
      <organization>Innocoll</organization>
      <phone>484-406-5206</phone>
      <email>lrussell@innocoll.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

